Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Everest Medicines Announces Inclusion in the MSCI Global Small Cap Indexes - MSCI China Index 2021-11-24 08:00
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-negative Breast Cancer Meets Primary Overall Response Rate Endpoint 2021-11-11 08:05
Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program 2021-11-08 08:15
Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program 2021-11-08 08:10
Everest Medicines Announces Share Repurchase Transaction Details 2021-11-01 08:00
Everest Medicines Initiates Submission of New Drug Application in Hong Kong for XeravaTM for the Treatment of Complicated Intra-abdominal Infections 2021-09-29 17:44
Everest Medicines Announces Approval of Investigational New Drug Application by China NMPA for SPR206 2021-09-24 13:56
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies 2021-09-23 06:00
Everest Medicines, Sinovent and SinoMab Announce Licensing Agreement for Global Development, Manufacturing and Commercialization of Novel BTK Inhibitor in Renal Diseases 2021-09-17 06:30
Everest Medicines Enters into Comprehensive Agreements with Providence Therapeutics to Advance mRNA Vaccines and Therapies, including COVID-19 Vaccines, in Asia Emerging Markets 2021-09-13 17:00
Everest Medicines Announces Half-Year 2021 Interim Results 2021-08-30 22:15
Everest Medicines Announces Up to HK$100 million Share Repurchase Program 2021-08-30 22:03
Everest Medicines Announces First Person Dosed in Global Phase 3 Registration Trial of Sacituzumab Govitecan-Hziy in China for Metastatic Urothelial Cancer 2021-08-26 21:40
Everest Medicines to Announce Half-Year 2021 Interim Results 2021-08-23 15:20
Everest Medicines Announces Approval of Clinical Trial Application by China NMPA for Phase 3 Trial of Xerava(TM) for Community-Acquired Bacterial Pneumonia 2021-08-05 13:12
Everest Medicines Receives Pediatric and Rare Severe Disease Priority Review Designation from Taiwan FDA for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer 2021-07-29 18:41
Everest Medicines Announces Strategic Collaboration with MediTrust Health Co., Ltd to Develop Novel Payment Solutions for Patients in China 2021-07-20 18:42
Everest Medicines Announces Strategic Collaboration with Medbanks Health Technology to Develop Innovative Healthcare Service Solutions for Patients in China 2021-07-13 19:47
Everest Medicines Announces Strategic Commercial Partnership with Global Technology Company, Tencent 2021-07-12 12:42
Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in ex-U.S. and ex-Asia Territories 2021-07-05 18:16
1 3 4 5 6 7